Skip to main content
SUTRO BIOPHARMA, INC. logo

SUTRO BIOPHARMA, INC. — Investor Relations & Filings

Ticker · STRO ISIN · US8693671021 LEI · 5493005U6P15VD25P851 US Manufacturing
Open in API
Filings indexed 586 across all filing types
Latest filing 2021-04-29 Proxy Solicitation & In…
Country US United States of America
Listing US STRO

About SUTRO BIOPHARMA, INC.

https://www.sutrobio.com/

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of precisely designed cancer therapeutics. The company leverages its proprietary, integrated cell-free protein synthesis platform to create novel antibody-drug conjugates (ADCs). This technology enables the development of next-generation ADCs, including those with single and dual payloads, which are designed to offer improved therapeutic profiles for patients with cancer. Sutro is advancing its own pipeline of clinical-stage product candidates to address areas of significant unmet medical need.

Recent filings

Filing Released Lang Actions
DEF 14A
Proxy Solicitation & Information Statement
2021-04-29 English
FORM 4 SUBMISSION
Director's Dealing
2021-04-20 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes a milestone payment from Merck to Sutro Biopharma related to a collaboration, which is a specific event update. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is not a proxy, governance, or management report. It is a regulatory announcement of a material event, fitting the category of Regulatory Filings (RNS). The document length is about 5,096 characters, which is consistent with a typical 8-K filing. Therefore, the best classification is Regulatory Filings (RNS) with high confidence.
2021-04-15 English
S-3ASR
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is a registration statement for securities offerings under the Securities Act of 1933. It includes a prospectus for the offering of common stock, preferred stock, debt securities, warrants, subscription rights, and units. The document is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, confirming it is not merely an announcement but the actual registration statement/prospectus filing.
2021-04-02 English
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Sutro Biopharma, Inc. It registers additional shares of common stock under the company's 2018 Equity Incentive Plan and 2018 Employee Stock Purchase Plan. The document includes details about the registration fee, incorporation by reference of prior filings, and exhibits related to the stock plans. Form S-8 is specifically used for registering securities to be offered to employees under employee benefit plans. This type of filing is related to share issuance and capital changes, not a financial report, management change, or other categories. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and content confirm it is the registration statement itself, not just an announcement or a certification, so it is not RPA or RNS.
2021-03-18 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated March 18, 2021. It announces the issuance of a press release regarding financial results for the year ended December 31, 2020. The text explicitly states that the information is being furnished and not filed, and includes a press release as an exhibit. The document itself does not contain detailed financial statements or substantive financial data, but rather announces the release of financial results. The length is 3520 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings and announcements that do not contain full financial reports.
2021-03-18 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.